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Background Untreated sexually transmitted infections
(STIs) and bacterial vaginosis (BV) cause genital
inflammation and increase the risk of HIV infection.
WHO-recommended syndromic STI and BV management
is severely limited as many women with asymptomatic
infections go untreated. The purpose of this cross-
sectional study was to evaluate genital cytokine profiles
as a biomarker of STIs and BV to identify women with
asymptomatic, treatable infections.
Methods Concentrations of 42 cytokines in
cervicovaginal lavages from 227 HIV-uninfected women
were measured using Luminex. All women were
screened for BV by microscopy and STIs using molecular
assays. Multivariate analyses were used to identify
cytokine profiles associated with STIs/BV.
Results A multivariate profile of seven cytokines
(interleukin (IL)-1α, IL-1β, tumour necrosis factor-β, IL-4,
fractalkine, macrophage-derived chemokine, and
interferon-γ) most accurately predicted the presence of a
treatable genital condition, with 77% classification
accuracy and 75% cross-validation accuracy (sensitivity
72%; specificity 81%, positive predictive value (PPV)
86%, negative predictive value (NPV) 64%).
Concomitant increased IL-1β and decreased IP-10
concentrations predicted the presence of a treatable
genital condition without a substantial reduction in
predictive value (sensitivity 77%, specificity 72%, PPV
82% and NPV 65%), correctly classifying 75% of the
women. This approach performed substantially better
than clinical signs (sensitivity 19%, specificity 92%, PPV
79% and NPV 40%).
Conclusions Supplementing syndromic management
with an assessment of IL-1β and IP-10 as biomarkers of
genital inflammation may improve STI/BV management
for women, enabling more effective treatment of
asymptomatic infections and potentially reducing their
risk of HIV infection.
INTRODUCTION
The prevalence of sexually transmitted infections
(STIs) and bacterial vaginosis (BV) in developing
countries is unacceptably high, particularly in
populations at the highest risk of HIV infection.1 2
STIs and BV cause genital inflammation2 that
potentially facilitates HIV infection by recruiting
HIV target cells,3 4 promoting HIV replication5
and reducing epithelial barrier integrity.6 Johnson
et al7 estimated that ∼50% of new HIV infections
in South African women were attributable to other
STIs in 2010.
In resource-limited settings, STIs and BV are
managed syndromically, according to the presence
of clinical signs and symptoms, rather than by more
costly laboratory-based diagnosis.8 However, a
large proportion of women with STIs or BV are
asymptomatic and are thus left untreated.2 9
Women with asymptomatic STIs have comparable
levels of genital inflammation to symptomatic
women, which are elevated compared with women
without an STI or BV.2 Previously, we found that
women with chlamydia or gonorrhoea, who were
mostly asymptomatic, had the highest genital cyto-
kine concentrations, while women with BV had
upregulated proinflammatory cytokines but down-
regulated chemokines and haematopoietic cyto-
kines.10 Many women in resource-limited settings
are thus likely to have STI-related inflammation
that remains unresolved, placing them at increased
risk of HIV infection and reproductive complica-
tions.11 There is an urgent need to improve STI
management for women in resource-limited set-
tings to identify asymptomatic infections more
effectively.
Laboratory-based nucleic acid amplification tests
(NAATs) are the gold standard for STI diagnosis.
Compared with syndromic management, NAATs
are costly and require experienced laboratory per-
sonnel and specialised equipment, which are often
lacking in resource-limited settings.8 In addition,
these tests do not offer immediate results and trans-
mission of STIs or acquisition of HIV may occur
while patients await results. Patients often do not
return to the clinic for treatment, with return rates
as low as 37% in some studies.12 Rapid
point-of-care (POC) tests have been under develop-
ment for several years. A rapid test for chlamydia
with moderate sensitivity (63%) would result in
more patients being treated than a laboratory test
with a sensitivity of 94%, if the return rate were
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less than 65%.13 However, several antigen-detecting rapid tests
for STIs have yielded inconsistent predictive value.14–18 POC
NAATs for Chlamydia trachomatis, Neisseria gonorrhoeae and
Trichomonas vaginalis have been developed and show compar-
able predictive value to laboratory NAATs.19 20 Currently,
however, POC NAATs are likely too expensive for implementa-
tion in resource-limited settings.
Measurement of inflammatory cytokine biomarkers in genital
secretions using a rapid test may prove useful to identify women
with asymptomatic STIs or BV, providing immediate results. The
aim of this study was to evaluate the predictive value of poten-
tial genital cytokine biomarkers of STIs or BV.
METHODS
Study participants
This study included 227 HIV-uninfected women from Durban,
South Africa.2 10 In addition, to validate this approach in
HIV-infected individuals, 38 HIV-infected women from Durban
were included.21 Women provided informed consent, and this
study was approved by the University of KwaZulu-Natal and
University of Cape Town Faculty of Health Sciences Human
Research Ethics Committees (UCT REC REF: 025/2004).
Screening for STIs and BV
A gynaecological examination was performed and swabs were
collected from the anterior and posterior fornices and lateral
vaginal walls.2 Specimens were screened for discharge-causing
STIs (C. trachomatis, N. gonorrhoeae, Mycoplasma genitalium,
T. vaginalis) and herpes simplex virus (HSV) by PCR and BV
using Nugent’s criteria.2 Blood was screened for IgG antibodies
to HSV-2 gG-2 using ELISA (HerpeSelect, Focus Diagnostics,
USA). Treponema pallidum exposure was detected using Becton
Dickinson Macro-Vue Rapid Plasma Reagin card and haem-
agglutination tests (ImmuTrep TPHA, Omega Diagnostics, UK).
As HSV and T. pallidum have long periods of latency, during
which time they would likely be undetectable in the genital tract
by PCR or inflammatory biomarkers, except in the case of
asymptomatic HSV shedding, an inflammatory biomarkers tool
would not be a good strategy to manage these infections, as it
would likely miss women who do not have primary infection,
reactivated infection or are not shedding HSV at the time.
Therefore, we aimed to identify women with treatable,
discharge-causing conditions (BV, T. vaginalis, C. trachomatis,
M. genitalium, N. gonorrhoeae).
Cytokine measurements
Cervicovaginal lavages (CVLs) were collected using 10 ml sterile
saline, centrifuged and supernatants stored at −80°C.2 CVLs
were not collected from menstruating participants. The concen-
trations of 42 cytokines were measured using human cytokine
LINCOplex kits (LINCO Research, USA): Epidermal growth
factor, eotaxin/CCL11, fibroblast growth factor-2, fms-like tyro-
sine kinase-3 ligand, fractalkine/CX3CL1, granulocyte colony
stimulating factor, granulocyte macrophage colony stimulating
factor, growth-related oncogene family (CXCL1-CXCL3), inter-
feron (IFN)-α, IFN-γ, interleukin (IL)-1α, IL-1β, IL-1Ra, IL-2,
IL-3, IL-4, IL-5, IL-6, IL-7, IL-8/CXCL8, IL-9, IL-10, IL-12p40,
IL-12p70, IL-13, IL-15, IL-17, IFN-γ-induced protein 10
(IP-10)/CXCL10, monocyte chemotactic protein (MCP-1)/
CCL2, MCP-3/CCL7, macrophage-derived chemokine (MDC)/
CCL22, macrophage inflammatory protein (MIP-1α)/CCL3,
MIP-1β/CCL4, platelet-derived growth factor (PDGF)-AA,
PDGF-AB/BB, RANTES/CCL5, sCD40L, soluble IL-2 receptor
α, transforming growth factor-α, tumour necrosis factor
(TNF)-α, TNF-β, and vascular endothelial growth factor.
Cytokine lower limits of detection ranged between 0.01 and
27.65 pg/mL. The data were collected using a Bio-Plex
Suspension Array Reader (Bio-Rad Laboratories Inc, USA). The
cytokines identified as the best biomarkers of STIs/BV were also
measured in the same samples from HIV-uninfected women
using Human Inflammation and Chemokine Cytometric Bead
Array (CBA) kits (BD Biosciences, USA). Cytokine concentra-
tions below the lower limit of detection were reported as the
mid-point between the lowest concentrations measured and
zero.
Y-chromosome amplification
DNA was extracted from CVL pellets using the Roche
MagNAPure LC DNA Isolation Kit I (Roche Applied Science,
Indianapolis, Indiana, USA). A region of the TSPY1 gene on the
Y-chromosome was amplified using real-time qPCR
(PrimerDesign Ltd, UK) and a Roche LightCycler 480 (Roche
Diagnostics, Switzerland).
Statistical analysis
Statistical analyses were performed using STATA (StataCorp,
USA) and Matlab (Mathworks, USA). Nonparametric receiver
operating characteristic (ROC) curves were used to compare
the predictive values of each cytokine. Logistic regression was
used to determine the variables that were together most pre-
dictive of the presence of an STI/BV. Youden’s index was used
to determine appropriate cutoffs for each cytokine, assuming
that sensitivity and specificity are of equal importance. Partial
least squares discriminant analysis (PLSDA)22 was used to
determine cytokine profiles that best distinguished between
individuals with and without an STI/BV. The data were nor-
malised with mean centring and variance scaling.
Cross-validation was performed by iteratively excluding
random subsets of data during model calibration, and using
excluded data to test model predictions. To identify the
optimal minimum biomarker profile for STI/BV diagnosis and
reduce the risk of over-fitting, the least absolute shrinkage and
selection operator (LASSO) method for regression and shrink-
age was used.23
RESULTS
Description of study participants
Fifty-three percent of the 227 HIV-uninfected women had BV
and 29% were PCR positive for a treatable discharge-causing
STI (C. trachomatis, N. gonorrhoeae, M. genitalium, T. vagina-
lis). Despite the high prevalence of STIs and BV, only 34/227
women (15%) had visible cervicovaginal discharge and none
had genital ulceration (table 1).
Genital cytokine profiles identify HIV-uninfected women
with BV and/or treatable discharge-causing STIs
A PLSDA model including all 42 cytokines distinguished
between women with an STI or BV and women without STIs/
BV with 78% classification accuracy, and 74% cross-validation
accuracy (figure 1A). Women with an STI/BV clustered in the
positive region of latent variable 1 (LV1; figure 1A), indicating
their cytokine profiles were characterised by upregulation of
cytokines positively loaded on LV1, and comparative downregu-
lation of cytokines loaded negatively onto LV1 (figure 1B). The
model of all 42 cytokines classified women with 74% sensitivity,
80% specificity, 86% positive predictive value (PPV) and 65%
negative predictive values (NPV; table 2).
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We then used LASSO to eliminate cytokines that did not sig-
nificantly contribute to group classification. A profile of seven
cytokines remained, that classified with similar predictive
strength (table 2: 77% classification accuracy, 72% sensitivity,
81% specificity, 86% PPV and 64% NPV), and slightly better
cross-validation accuracy compared with the model including all
cytokines (75%; figure 1C). In this reduced model, TNF-β,
IL-1α and IL-1β elevation with comparative reduction in IFN-γ,
IL-4, MDC and fractalkine was associated with the STI/BV
group (figure 1D).
IL-1β and IP-10 are predictive of BV and treatable
discharge-causing STIs in HIV-uninfected women
As a diagnostic test including seven biomarkers may be too
expensive for implementation in resource-limited settings, we
evaluated whether it would be possible to decrease the number
of biomarkers included, without a substantial reduction in pre-
dictive value. The predictive value of each of the 42 cytokines
was evaluated individually using nonparametric ROC analysis
(figure 2). IL-1α and IL-1β had the largest ROC areas, indicating
that these cytokines had the highest predictive power. Of the
cytokines that were inversely associated with the presence of an
STI or BV, IP-10 had the best predictive power. It was found
that a marginally higher percentage of women were correctly
classified using IL-1β (70.5%; cutoff ≥−0.37 log10 pg/mL)
compared with IL-1α (69.6%; cutoff ≥1.96 log10 pg/mL) and
IP-10 (63.9%; cutoff <1.30 log10 pg/mL; online supplementary
figure S1).
To determine whether inclusion of a second cytokine would
improve the predictive value of IL-1β, each of the other 41
cytokines was stepwise added to IL-1β using a logistic
regression model building procedure. A model including IL-1β
and IP-10 was best predictive of the presence of an STI/BV, cor-
rectly classifying 75% of women with a sensitivity of 77%,
specificity of 72%, PPV of 82% and NPV of 65% (table 2).
Inclusion of a third cytokine, IL-1α, correctly classified 76% of
women (sensitivity 72%, specificity 81%, PPV 86% and NPV
64%) and significantly improved the fit of the model (likeli-
hood ratio (LR) χ2: 14.61, p=0.0001); however, this repre-
sented only a marginal improvement compared with IL-1β and
IP-10 alone.
Upon evaluation of model performance by reapplication of
the model to 10 randomly chosen three-quarter subsets of the
cohort, 72–80% of women were correctly classified.
Furthermore, the relationships between IL-1β and IP-10 and
the presence of an STI/BV remained statistically significant and
the directionality of the relationships remained constant, indi-
cating that the model estimates are stable and that the biomar-
kers had similar accuracy in each subset. To evaluate whether
the method of cytokine measurement influenced the results,
IL-1β and IP-10 concentrations were measured using CBA
(table 2). The predictive value of IL-1β and IP-10 was similar
when these cytokines were measured using CBA (sensitivity
83%, specificity 61%, PPV 78%, NPV 69%; table 2), compared
with Luminex.
To determine whether the predictive value of IL-1β and IP-10
was influenced by age, injectable contraceptive use, yeast and
seminal fluid, which may influence genital cytokine concentra-
tions,24–27 each factor was added to the model. It was found
that age (LR χ2: 0.55, p=0.4601), injectable contraceptive use
(LR χ2: 0.15, p=0.6945), yeast infections (LR χ2: 1.71,
p=0.1912) or seminal plasma exposure (LR χ2: 2.93,
p=0.0869) did not significantly influence the fit of the model.
Although the number of casual sexual partners during the past
3 months was not associated with IL-1β or IP-10 concentrations,
inclusion in the model marginally improved the fit (LR χ2: 5.53,
p=0.0187).
Using the IL-1β and IP-10 model, 100% of women with M.
genitalium, 90% of women with chlamydia, 77% of women
with gonorrhoea and 70% of women with trichomoniasis were
identified. Of the 24 women who did not have an STI/BV but
were incorrectly classified as positive, 38% (9/24) had inter-
mediate flora, compared with 13% of women in the whole
cohort (30/227) (p=0.0048). This indicates that intermediate
flora may have caused altered cytokine concentrations in some
women. However, the inclusion of women with intermediate
flora did not influence the predictive value of the model (sensi-
tivity 74%, specificity 78%, PPV 89%, NPV 56%). Of the 33
women who had a STI/BV but were incorrectly classified as
negative, most (31/33; 94%) had trichomoniasis or BV, which
were previously found to be less inflammatory.10 One of the
remaining women had chlamydia, the other had gonorrhoea
and two of the women with trichomoniasis also had
gonorrhoea.
Comparing cytokine biomarkers with clinical signs of an STI
or BV
IL-1β and IP-10 biomarkers were found to predict the presence
of an STI or BV with substantially better sensitivity compared
with clinical signs (sensitivity 19%, specificity 92%, PPV 79%,
NPV 40%). Although addition of clinical signs to the IL-1β and
IP-10 model significantly improved the fit (LR χ2: 6.66,
p=0.0099), the percentage of women correctly classified
remained unchanged (75% (sensitivity 74%, specificity 78%,
PPV 86% and NPV 64%)).




Age (median (range)) 36 (18–58) 24 (18–59)
n/total (%) n/total (%)
Black African race 224/227 (98.7) 38/38 (100)
Oral contraception 5/226 (2.2) 0/38 (0)
Injectable hormone contraception 63/226 (27.9) 13/38 (34.2)
No active STI or BV 86/227 (37.4) 7/38 (18.4)
Treatable discharge-causing STI or BV 141/227 (62.1) 31/38 (81.6)
Trichomonas vaginalis (PCR+) 47/227 (20.7) 4/38 (10.5)
Chlamydia trachomatis (PCR+) 10/227 (4.4) 5/38 (13.2)
Neisseria gonorrhoeae (PCR+) 13/227 (5.7) 6/38 (15.8)
Mycoplasma genitalium (PCR+) 3/227 (1.3) 4/38 (10.5)
HSV-2 IgG seropositive 198/227 (87.2) 35/38 (92.1)
HSV (PCR+) 6/227 (2.6) 2/38 (5.3)
Treponema pallidum (RPR >1:4, TPHA
positive)
3/227 (1.3) 2/38 (5.3)
BV (Nugent score ≥7) 120/227 (52.9) 28/38 (73.7)
Yeast hyphae (n/total (%))* 19/173 (11.0) ND
Cervicovaginal discharge 34/227 (15.0) 7/38 (18.4)
Genital ulceration 0/227 (0.0) 4/38 (10.5)
Y chromosome detected 42/185 (22.7) ND
*Intact BV slides were available for 173/227 HIV-uninfected women for retrospective
analysis for yeast hyphae. Treatable discharge-causing STI includes T. vaginalis,
C. trachomatis, N. gonorrhoeae and M. genitalium.
BV, bacterial vaginosis; HSV, herpes simplex virus; ND, not done; RPR, rapid plasma
reagin; STI, sexually transmitted infections.
188 Masson L, et al. Sex Transm Infect 2016;92:186–193. doi:10.1136/sextrans-2015-052072
Basic science
group.bmj.com on March 13, 2018 - Published by http://sti.bmj.com/Downloaded from 
IL-1β and IP-10 are predictive of BV and treatable
discharge-causing STIs in HIV-infected women
As the HIV status of women using a cytokine test for STIs and
BV may not necessarily be known, it is important that these bio-
markers are also accurate in HIV-infected women, particularly
since STIs and BV are prevalent in these women. Therefore, we
investigated whether IL-1β and IP-10 would identify a STI or
BV in HIV-infected women (median 6 weeks post-infection).21
IL-1β and IP-10 were found to identify women with a STI or
BV with similar sensitivity in HIV-infected women (80%), but
improved specificity (100%), compared with HIV-uninfected
women (table 2).
DISCUSSION
The pro-inflammatory cytokine IL-1β and the chemokine IP-10
together were the most useful immunologic biomarkers that
could be used to diagnose treatable discharge-causing STIs and
BV. These biomarkers identified 77% of the HIV-uninfected
women who had an STI or BV, while only 19% of these women
were identified by clinical signs. Using these cytokines, 75% of
HIV-uninfected women were correctly classified as either STI/
BV-positive or negative, with a sensitivity of 77%, specificity of
72%, PPV of 82% and NPV of 65%. Similarly, in HIV-infected
women, these two biomarkers correctly identified 80% of
women with an STI or BV (sensitivity 80%, specificity 100%,
PPV 100%, NPV 54%).
The LASSO cytokine model that most accurately classified
women as STI/BV-positive or negative included seven cytokines
(IL-1α, IL-1β, TNF-β, IL-4, fractalkine, MDC and IFN-γ), cor-
rectly classifying 77% of HIV-uninfected women (sensitivity
72%, specificity 81%, PPV 86% and NPV 64%). However, as
reducing this model to only two cytokines, IL-1β and IP-10,
Figure 1 Identification of multivariate cytokine profiles associated with sexually transmitted infections and bacterial vaginosis (STIs/BV). A) Partial
least squares discriminant analysis (PLSDA) model of all 42 cytokines classified individuals with 78% overall accuracy for classification and 74%
accuracy for cross-validation (light blue: women with a STI/BV; dark blue: women with no STI/BV). B) Latent variable cytokine loadings indicate
multivariate cytokines associated with STIs/BV. Since individuals with an STI/BV cluster in the positive region of LV1 (A), cytokines positively loaded
on LV1 (B) are elevated in STI/BV profiles, while negative loadings are comparatively reduced. (C) To avoid over-fitting, the Least Absolute Shrinkage
and Selection Operator (LASSO) method for feature selection was used to eliminate cytokines that didn’t contribute to classification, and resulted in
a profile of seven cytokines that performed with 77% classification accuracy and 75% cross-validation accuracy. (D) Loadings in the reduced model
indicated that the STI/BV profile consists of elevated interleukin (IL)-1β, IL-1α, and tumour necrosis factor (TNF)-β, with comparatively reduced
interferon (IFN)-γ, IL-4, macrophage-derived chemokine (MDC) and fractalkine.
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diagnosis (n) Sensitivity Specificity PPV NPV
Pos Neg % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Selection of biomarkers by partial least squares discriminant analysis (PLSDA)
HIV− All cytokines N/A Luminex Pos 105 17 74 (66 to 81) 80 (70 to 88) 86 (79 to 92) 65 (55 to 74)
Neg 36 68
HIV− IL-1α, IL-1β, TNF-β, IL-4, fractalkine, MDC,
IFN-γ
N/A Luminex Pos 102 16 72 (64 to 80) 81 (71 to 89) 86 (79 to 92) 64 (54 to 73)
Neg 39 69
Selection of biomarkers by logistic regression
HIV− IL-1β+IP-10 0.596882 Luminex Pos 108 24 77 (69 to 83) 72 (61 to 81) 82 (74 to 88) 65 (55 to 75)
Neg 33 62
HIV− IL-1α+IP-10 0.595988 Luminex Pos 100 22 71 (63 to 78) 74 (64 to 83) 82 (74 to 88) 61 (51 to 70)
Neg 41 64
HIV− IL-1β+IP-10 0.549353 CBA† Pos 115 33 83 (76 to 89) 61 (49 to 71) 78 (70 to 84) 69 (57 to 79)
Neg 23 51
HIV− IL-1β+IP-10+IL-1α 0.672886 Luminex Pos 102 16 72 (64 to 80) 81 (72 to 89) 86 (79 to 92) 64 (54 to 73)
Neg 39 70
HIV+ IL-1β+IP-10‡ 0.840123 Luminex Pos 24 0 80 (61 to 92) 100 (59 to 100) 100 (86 to 100) 54 (25 to 81)
Neg 6 7
HIV− Discharge or ulceration N/A N/A Pos 27 7 19 (13 to 26) 92 (84 to 97) 79 (62 to 91) 40 (33 to 48)
Neg 115 78
HIV+ Discharge or ulceration N/A N/A Pos 10 0 32 (17 to 51) 100 (59 to 100) 100 (69 to 100) 25 (11 to 45)
Neg 21 7
*Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium and Trichomonas vaginalis were assessed by PCR.
†Cytokine concentrations were measured for a subset of 222/227 women using CBA.
‡IP-10 data was missing for one HIV positive participant who only had sufficient sample available for a high sensitivity Luminex assay.























only decreased the percentage of women correctly classified by
2%, the expense of including five additional biomarkers would
likely outweigh the benefit. We thus propose that IL-1β in
combination with IP-10 would be the most cost-effective bio-
markers for a rapid POC test for identifying asymptomatic
discharge-causing STIs and BV. IL-1β upregulation predicted the
presence of an STI/BV, while IP-10 was inversely associated. This
is because IL-1β was significantly upregulated in women with BV
or an STI, while IP-10 was downregulated in women who had
BV.10 IL-1β allowed for identification of women with high levels
of genital inflammation, while IP-10 differentiated women with
BV who had more moderate levels of inflammation.
Following the identification of women using IL-1β and IP-10,
the approach implemented in the clinical setting would likely
depend on resource availability. In regions where resources are
not limited, women identified may be referred for comprehen-
sive laboratory STI/BV testing. In resource-limited settings,
where this may not be feasible because of the expense of labora-
tory testing, women with a positive cytokine POC test result
could be offered immediate treatment using the same antibiotics
offered to women with vaginal discharge (WHO syndromic
management guidelines). Immediate treatment of these women,
in the absence of aetiological diagnoses, does raise concern
about possible overtreatment. However, cytokine biomarkers
predicted the presence of an STI/BV with marginally higher
PPVs (fewer false positives) than clinical signs, suggesting that
an inflammation biomarker test would not result in increased
overtreatment rates compared with syndromic management. In
this study, probability cutoffs were set objectively using
Youden’s index. In practice, cytokine concentration cutoffs
would depend on the strategy used to manage the women iden-
tified as having inflammation. Should all women identified be
referred for laboratory STI/BV testing, one may wish to opti-
mise the sensitivity by adjusting the absolute concentration
cutoffs, whereas should women identified be immediately
treated with antibiotics, optimisation of the specificity would
reduce overtreatment.
As only common STIs and BV were evaluated, women who
were “falsely” classified as positive may have had inflammation
caused by other infections, including human papillomavirus,
Schistosoma, Fusobacterium, Aerococcus, Sneathia, Gemella,
Mobiluncus and Prevotella and other potentially inflammatory
microorganisms that are not necessarily detected by the labora-
tory methods used in this study.28–30 Only one woman who did
not have a treatable discharge-causing STI or BV was HSV PCR
+ and none had a T. pallidum rapid plasma reagin >1:4 with a
positive Treponema pallidum haemagglutination (TPHA) test;
therefore, these infections were not the cause of the majority of
false-positive results in this cohort. Although reactivation of
HSV or T. pallidum, or HSV shedding, may contribute to false-
positive results in other cohorts, these infections may be accom-
panied by genital ulcers and condylomata lata, respectively,
which can be managed syndromically8 and women who have
syphilis can be identified using an existing T. pallidum rapid
test. We found that age, yeast infections, semen exposure and
injectable hormone contraception, each previously shown to
influence genital cytokine concentrations,24–27 did not influence
the predictive value of the cytokine model. A limitation of this
study was that we did not evaluate the impact of douching, the
use of anti-inflammatories, antibiotics or antiretrovirals, men-
strual cycle phase, pregnancy, cervical ectopy and vaginal prac-
tices. Although we found that IL-1β and IP-10 performed well
in separate cohorts of HIV-uninfected and HIV-infected
women, it would be important to evaluate these biomarkers in a
cohort of both HIV-infected and uninfected women, as HIV
infection may influence genital cytokine concentrations and
HIV status of women using the test may not necessarily be
known. Women who had an STI or BV, but were classified as
negative using IL-1β and IP-10 biomarkers were not identified
because they had low levels of genital inflammation and may
have resolving or less severe infections, or may have been
recently treated and may have PCR positive results due to the
presence of dead organisms. Measurement of inflammatory
cytokine biomarkers likely identifies women with severe inflam-
matory infections who are at the greatest risk of reproductive
complications and HIV acquisition.
An inexpensive biomarker rapid test could be used together
with the current syndromic management protocol, particularly
in resource-limited settings where laboratory diagnosis is not
feasible, to increase the number of women treated for genital
Figure 2 Genital cytokine concentrations predict the presence of sexually transmitted infections (STIs) and bacterial vaginosis (BV). Receiver
Operating Characteristic (ROC) areas for each of the cytokines is shown. Cytokines with a ROC area of 0.5 have no predictive value. Cytokines with
a ROC area >0.5 are positively associated with the presence of an STI or BV, whereas cytokines with a ROC area <0.5 are inversely associated.
Cytokines indicated by dots were found to be significantly associated with the presence of a treatable discharge-causing STI or BV, whereas those
indicated by circles were not significantly associated.
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infections. A reduction in the prevalence of discharge-causing
STIs and BV may reduce the incidence of HIV infection and
improve reproductive health.
Key messages
▸ Interleukin (IL)-1β and IP-10 concentrations in female genital
secretions predicted the presence of a genital condition with
77% sensitivity, 72% specificity, 82% positive predictive
value (PPV) and 65% negative predictive value (NPV).
▸ These cytokine biomarkers performed substantially better
than clinical signs (sensitivity 19%, specificity 92%, PPV
79% and NPV 40%).
▸ Supplementing syndromic management with an assessment
of IL-1β and IP-10 as biomarkers of genital inflammation
may improve sexually transmitted infections and bacterial
vaginosis management for women.
▸ This strategy may enable more effective treatment of
asymptomatic infections and potentially reduce HIV
incidence and reproductive complications in women.
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